Original article Thierry Lefevre
TAVR and Anticoagulation: Direct Anticoagulant Agents or Vitamin K Inhibitors?
In some patients, using an anticoagulant agent is not an option, it is just prescribed. Based on the French TAVR registry, this research compared long-term mortality, bleeding, and ischemic events after valve implantation. A comparison was made between TAVR and direct vs. classic anticoagulant agents—good old proven and reversible vitamin K inhibitors. Cardiologists, hematologists, clinicians, and<a href="https://solaci.org/en/2021/09/29/tavr-and-anticoagulation-direct-anticoagulant-agents-or-vitamin-k-inhibitors/" title="Read more" >...</a>
Do NOACs Result in Any Benefit in TAVR?
Courtesy of Dr. Carlos Fava. The need for anticoagulation after transcatheter aortic valve replacement (TAVR) is over 15% according to different reports and, so far, no one has analyzed in depth whether new oral anticoagulant agents (non-vitamin K oral anticoagulants [NOACs]) result in superior benefit compared with classic vitamin K antagonists (VKAs). This study analyzed<a href="https://solaci.org/en/2019/08/23/do-noacs-result-in-any-benefit-in-tavr/" title="Read more" >...</a>
VALIDATE-SWEDEHEART: bivalirudin seems to be losing ground
Another important work that does not see the benefits of bivalirudin over heparin as monotherapy as regards both efficacy (death and MI) and safety end points (bleeding) in patients undergoing acute myocardial infarction with and without ST elevation. The study VALIDATE-SWEDEHEART, presented at ESC, simultaneously published in the New England Journal of Medicine, randomized 6000 patients<a href="https://solaci.org/en/2017/09/04/validate-swedeheart-bivalirudin-seems-to-be-losing-ground/" title="Read more" >...</a>
Transradial access shows no benefit of bivalirudin
The aim of this study was to compare bivalirudin against heparin in patients with ST elevation acute myocardial infarction undergoing transradial primary PCI. Both bivalirudin and the transradial access are strategies aimed at reducing bleeding complications in patients undergoing acute MI. However, the benefit of their combined use is not year clear. Even though<a href="https://solaci.org/en/2017/06/21/transradial-access-shows-no-benefit-of-bivalirudin/" title="Read more" >...</a>
Bivalirudin reduces bleeding rate in carotid stenting
Courtesy of Dr. Carlos Fava Bivalirudin has been shown to reduce bleeding in carotid stenting and maintain its efficacy. Even though carotid stenting has shown benefits, these remain unclear. With this in mind, four studies were analyzed (one randomized) including 7,784 patients undergoing carotid stenting with unfractioned heparin vs. bivalirudin. No difference was<a href="https://solaci.org/en/2017/05/08/bivalirudin-reduces-bleeding-rate-in-carotid-stenting/" title="Read more" >...</a>
Cardiovascular Events Reduction: Bivalirudin or Heparin?
The MATRIX study did not find a clear advantage of bivalirudin over unfractioned heparin to reduce major adverse cardiovascular events (MACE) or net cardiovascular adverse events (NCAE) in patients undergoing acute coronary syndrome receiving PCI. This new analyzis confirms there is no difference in ischemic and thrombotic events in patients with acute coronary syndrome<a href="https://solaci.org/en/2016/10/19/cardiovascular-events-bivalirudin-heparin/" title="Read more" >...</a>
Bivalirudin or Heparin to Decrease Cerebral Embolization Post TAVI?
Cerebral embolization is a relatively frequent complication during transcatheter aortic valve replacement (TAVR). The hypothesis behind this study is that the incidence of cerebral embolization might be decreased by anticoagulation with bivalirudin, instead of heparin. The first study objective was to determine the proportion of patients with new cerebral embolus after TAVI and<a href="https://solaci.org/en/2016/08/19/bivalirudin-or-heparin-to-decrease-cerebral-embolization-post-tavi/" title="Read more" >...</a>
Taxas de trombose de stent em pacientes com STEMI
Fundamentos e objetivos: Em estudos recentes sobre intervenção coronária percutânea primária (PPCI), a bivalirudina em comparação com a heparina tem sido associada ao aumento do risco de trombose de stent (ST), com taxas relatadas de ST muito variáveis. O objetivo deste estudo foi descrever a incidência de “mundo real” e os resultados de ST definitiva,<a href="https://solaci.org/en/2015/06/24/congress-item-9072/" title="Read more" >...</a>